Education
About Us
Working with TipRanks
Follow Us
Lipella Pharmaceuticals, Inc. (LIPO)
:LIPO
RESEARCH TOOLSreports
LIPO Stock Chart & Stats
Day’s Range― - ―
52-Week Range$2.02 - $12.00
Previous CloseN/A
Volume96.41K
Average Volume (3M)53.34K
Market Cap
$6.02M
Enterprise ValueN/A
Total Cash (Recent Filing)$2.11M
Total Debt (Recent Filing)$115.70K
Price to Earnings (P/E)―
Beta-0.17
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.78
Shares Outstanding2,548,811
10 Day Avg. Volume35,757
30 Day Avg. Volume53,337
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)6.48
Price to Cash Flow (P/CF)-1.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$10.00Price Target Upside323.73% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Lipella Pharmaceuticals, Inc. News
PremiumMarket News
3 Penny Stocks to Watch Now, 2/13/25
PremiumCompany Announcements
Lipella Pharmaceuticals Gains FDA Approval for LP-310
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsLipella announced positive results from its P2a study of LP-310 in oral lichen planus (OLP), highlighting data from the first cohort which received the lowest treatment dose of 0.25mg.
Patent And Intellectual PropertyLipella announced the receipt of US Patent for its liposomal drug delivery platform, extending exclusivity to 2035.
Regulatory ApprovalFDA granted approval for an expanded access program (EAP) for LP-310, its oral rinse formulation of tacrolimus, for the treatment of oral lichen planus (OLP).
Bears Say
Funding And Capital NeedsThe company will likely need to raise additional capital to fund its ongoing programs.
Market EnvironmentShares have pulled back due to challenging biotech markets, financing environment, and lack of significant catalysts.
---
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
LIPO FAQ
What was Lipella Pharmaceuticals, Inc.’s price range in the past 12 months?
Lipella Pharmaceuticals, Inc. lowest stock price was $2.02 and its highest was $12.00 in the past 12 months.
What is Lipella Pharmaceuticals, Inc.’s market cap?
Lipella Pharmaceuticals, Inc.’s market cap is $6.02M.
When is Lipella Pharmaceuticals, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Lipella Pharmaceuticals, Inc.’s earnings last quarter?
Lipella Pharmaceuticals, Inc. released its earnings results on Mar 31, 2023. The company reported -$1.487 earnings per share for the quarter, missing the consensus estimate of N/A by -$1.487.
Is Lipella Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Lipella Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Lipella Pharmaceuticals, Inc. pay dividends?
Lipella Pharmaceuticals, Inc. does not currently pay dividends.
What is Lipella Pharmaceuticals, Inc.’s EPS estimate?
Lipella Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Lipella Pharmaceuticals, Inc. have?
Lipella Pharmaceuticals, Inc. has 2,548,811 shares outstanding.
What happened to Lipella Pharmaceuticals, Inc.’s price movement after its last earnings report?
Lipella Pharmaceuticals, Inc. reported an EPS of -$1.487 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.622%.
Which hedge fund is a major shareholder of Lipella Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in LIPO
---
Company Description
Lipella Pharmaceuticals, Inc.
Lipella Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on developing drugs by reformulating the active agents in existing generic drugs and optimizing these reformulations for various applications. It is developing LP-10, a formulation of tacrolimus that is in Phase IIa clinical trial for patients with radiation-induced hemorrhagic cystitis; and LP-310, a formulation of tacrolimus for the treatment of oral lichen planus. The company was incorporated in 2005 and is based in Pittsburgh, Pennsylvania.
---
LIPO Stock 12 Month Forecast
Average Price Target
$10.00
▲(323.73% Upside)
Technical Analysis
EyePoint Pharmaceuticals
―
Xoma
―
Aurinia Pharmaceuticals
―
Ocugen
―
Kala Pharmaceuticals
―
Best Analysts Covering LIPO
1 Year
1 Year Success Rate
0/7 ratings generated profit
1 Year Average Return
-43.90%
reiterated a buy rating 2 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -43.90% per trade.
---